Villardita C, Parini J, Grioli S, Quattropani M, Lomeo C, Scapagnini U
Department of Neurology, School of Medicine, University of Catania, Italy.
J Neural Transm Suppl. 1987;24:293-8.
40 out-patients with a mild to moderate degree of dementia (11 less than or equal to MMSE less than 24) participated in a between-subjects (n = 20 + 20) double-blind placebo-controlled randomized trial comparing the effects of oxiracetam 800 mg bid and placebo during 90 days of treatment. At the end of therapy, statistical analysis (ANOVA) detected significant differences between groups: after oxiracetam treatment, improvements were observed on Mini Mental State Examination, Auditory Continuous Performance Test, Block Tapping Test, Word Fluency and Instrumental Activities of Daily Living. No side effects were observed. In conclusion, in the present population of patients with mild to moderate degree dementia, 1600 mg/day of oxiracetam was effective in enhancing both attentional activities and other, more complex, neuropsychological functions.
40名轻度至中度痴呆患者（11≤MMSE＜24）参与了一项组间（n = 20 + 20）双盲安慰剂对照随机试验，比较了90天治疗期间800毫克/次、每日两次的奥拉西坦与安慰剂的效果。治疗结束时，统计分析（方差分析）发现组间存在显著差异：奥拉西坦治疗后，简易精神状态检查表、听觉持续性操作测试、敲击方块测试、语言流畅性和日常生活工具性活动均有改善。未观察到副作用。总之，在目前轻度至中度痴呆患者群体中，每日1600毫克的奥拉西坦可有效增强注意力活动及其他更复杂的神经心理功能。
